Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company was founded by Lishan Aklog on May 8, 2018 and is headquartered in New York, NY.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Veris Health and The Ohio State University Comprehensive Cancer Center have launched the commercial phase of their strategic partnership to deploy the Veris Cancer Care Platform across the cancer center. - The digital platform provides remote physiological monitoring, symptom reporting, and telehealth capabilities to enhance personalized cancer care and reduce unplanned hospitalizations. - Cancer patients receive a VerisBox of connected healthcare devices that transmit physiologic data to clinicians via cellular connections, with a complementary smartphone app for symptom reporting. - The partnership expands from pilot phase to full engagement across The James, including launching a clinical registry for patients enrolled on the platform.
- ProPhase Labs has established a Clinical Science Advisory Board to accelerate commercialization of its BE-Smart molecular test for esophageal disease detection and cancer risk management. - The BE-Smart test measures real-time protein activity using mass spectrometry from a single tissue section, delivering results in under 7 days with seamless integration into existing clinical workflows. - The company targets a $7-14 billion market opportunity with approximately 7 million annual endoscopies performed on patients at risk of esophageal cancer in the United States. - The advisory board includes test inventor Dr. Joe Abdo and industry veteran James McCullough, with clinical validation data currently under peer review at the Journal of Clinical Gastroenterology and Hepatology.
- University Hospitals and Case Western Reserve University launch an $8 million NIH-funded clinical trial to evaluate EsoCheck and EsoGuard technologies for detecting Barrett's Esophagus in non-GERD patients. - The multi-center study aims to screen 800 participants across five major institutions, addressing a critical gap in current screening guidelines that exclude patients without GERD symptoms. - The innovative screening approach using FDA-approved technologies could revolutionize early detection of esophageal precancer, potentially improving outcomes for a cancer with only 20% five-year survival rate.
- Lucid Diagnostics has partnered with LEAA Health to offer its EsoGuard Esophageal DNA Test to concierge medicine patients on a cash-pay basis, targeting the growing $10.9 billion concierge medicine market projected by 2032. - Highmark Blue Cross Blue Shield has issued the first positive commercial insurance coverage policy for Lucid's EsoGuard test in New York state, marking a significant milestone that could influence other insurers to follow suit. - The EsoGuard test provides non-invasive screening for esophageal precancer and cancer in patients with gastroesophageal reflux disease (GERD), potentially enabling earlier intervention and improved patient outcomes.
- A new study demonstrates the clinical utility of Lucid Diagnostics' EsoGuard test for detecting Barrett's Esophagus. - The study showed a high patient compliance rate of 85% with referrals to confirmatory upper endoscopy after positive EsoGuard results. - EsoGuard effectively triages patients at increased risk for esophageal precancer, reducing the need for invasive procedures. - The test exhibits near-perfect provider decision impact, with consistent referral patterns based on test results.
